Modimelanotide(Modimelanotide) - 药物靶点：MC1R x MC3R x MC4R x MC5R_专利_临床

概要

基本信息

药物类型

合成多肽

别名

Ac-(Lys)6-alphaMSH

+ [1]

靶点

MC1R x MC3R x MC4R x MC5R

作用机制

MC1R激动剂(黑素皮质素受体1激动剂)、MC3R激动剂(黑素皮质素受体3激动剂)、MC4R激动剂(黑素皮质素受体4激动剂)

+ [1]

治疗领域

心血管疾病泌尿生殖系统疾病呼吸系统疾病+ [1]

在研适应症-

非在研适应症

急性肾损伤主动脉瘤心血管疾病+ [7]

原研机构

Zealand Pharma A/S

在研机构-

非在研机构

Action Pharma A/S

AbbVie, Inc.

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C113H181N33O25S

InChIKeyWHRVKPBBRZHWTN-ZHHKRVSMSA-N

CAS号926277-68-1

序列信息

Sequence Code 14547742

来源: *****

关联

6

项与 Modimelanotide 相关的临床试验

NCT01897519 / Terminated临床2期

A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Major Surgery

This study will evaluate the safety and efficacy of ABT-719 in patients undergoing high risk major surgery.

开始日期2013-05-01

申办/合作机构

AbbVie, Inc.

NCT01777165 / Completed临床2期

A Phase 2b, Randomized, Double-Blind,Placebo-Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery

This study will evaluate the safety and efficacy of ABT-719 in preventing acute kidney injury in patients undergoing high risk cardiac surgery.

开始日期2013-02-01

申办/合作机构

AbbVie, Inc.

EUCTR2010-022630-92-DK / Not yet recruitingN/A

An Explorative Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery

开始日期2010-11-05

申办/合作机构

Action Pharma A/S

100 项与 Modimelanotide 相关的临床结果

登录后查看更多信息

100 项与 Modimelanotide 相关的转化医学

登录后查看更多信息

100 项与 Modimelanotide 相关的专利（医药）

登录后查看更多信息

15

项与 Modimelanotide 相关的文献（医药）

2018-05-01·Pediatric Nephrology3区 · 医学

Acute kidney injury: emerging pharmacotherapies in current clinical trials

3区 · 医学

Review

作者: Devarajan, Prasad ; Benoit, Stefanie Woolridge

Acute kidney injury (AKI) is a significant source of morbidity and mortality in pediatric patients, affecting more than one quarter of critically ill children. Despite significant need, there are no targeted therapies to reliably prevent or treat AKI. Recent advances in our understanding of renal injury and repair signaling pathways have enabled the development of several targeted pharmaceuticals. Here we review emerging pharmacotherapies for AKI that are currently in clinical trials. Categorized by their general mechanism of action, the therapies discussed include anti-inflammatory agents (recAP, AB103, ABT-719), antioxidants (iron chelators, heme arginate), vasodilators (levosimendan), apoptosis inhibitors (QPI-1002), and repair agents (THR-184, BB-3, mesenchymal stem cells).

2017-02-01·Expert Opinion on Investigational Drugs2区 · 医学

Recent early clinical drug development for acute kidney injury

2区 · 医学

Review

作者: Ross, James A ; Hughes, Jeremy ; Gallagher, Kevin M. ; Harrison, Ewen M ; O’neill, Stephen ; Wigmore, Stephen J

INTRODUCTIONDespite significant need and historical trials, there are no effective drugs in use for the prevention or treatment of acute kidney injury (AKI). There are several promising agents in early clinical development for AKI and two trials have recently been terminated. There are also exciting new findings in pre-clinical AKI research. There is a need to take stock of current progress in the field to guide future drug development for AKI. Areas covered: The main clinical trial registries, PubMed and pharmaceutical company website searches were used to extract the most recent clinical trials for sterile, transplant and sepsis-associated AKI. We summarise the development of the agents recently in clinical trial, update on their trial progress, consider reasons for failed efficacy of two agents, and discuss new paradigms in pre-clinical targets for AKI. Agents covered include- QPI-1002, THR-184, BB-3, heme arginate, human recombinant alkaline phosphatase (recAP), ciclosporin A, AB103, levosimendan, AC607 and ABT-719. Expert opinion: Due to the heterogenous nature of AKI, agents with the widest pleiotropic effects on multiple pathophysiological pathways are likely to be most effective. Linking preclinical models to clinical indication and improving AKI definition and diagnosis are key areas for improvement in future clinical trials.

2015-11-01·Antimicrobial Agents and Chemotherapy2区 · 医学

Protective Effect of Qnr on Agents Other than Quinolones That Target DNA Gyrase

2区 · 医学

Article

作者: Corcoran, Marian A. ; Hooper, David C. ; Jacoby, George A.

ABSTRACTQnr is a plasmid-encoded and chromosomally determined protein that protects DNA gyrase and topoisomerase IV from inhibition by quinolones. Despite its prevalence worldwide and existence prior to the discovery of quinolones, its native function is not known. Other synthetic compounds and natural products also target bacterial topoisomerases. A number were studied as molecular probes to gain insight into how Qnr acts. Qnr blocked inhibition by synthetic compounds with somewhat quinolone-like structure that target the GyrA subunit, such as the 2-pyridone ABT-719, the quinazoline-2,4-dione PD 0305970, and the spiropyrimidinetrione pyrazinyl-alkynyl-tetrahydroquinoline (PAT), indicating that Qnr is not strictly quinolone specific, but Qnr did not protect against GyrA-targeting simocyclinone D8 despite evidence that both simocyclinone D8 and Qnr affect DNA binding to gyrase. Qnr did not affect the activity of tricyclic pyrimidoindole or pyrazolopyridones, synthetic inhibitors of the GyrB subunit, or nonsynthetic GyrB inhibitors, such as coumermycin A1, novobiocin, gyramide A, or microcin B17.Thus, in this set of compounds the protective activity of Qnr was confined to those that, like quinolones, trap gyrase on DNA in cleaved complexes.

100 项与 Modimelanotide 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Modimelanotide	-	DB15314

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心血管疾病	临床2期	美国	AbbVie, Inc.	2013-05-01
心血管疾病	临床2期	丹麦	AbbVie, Inc.	2013-05-01
主动脉瘤	临床2期	丹麦	Action Pharma A/S	2010-10-01
冠心病	临床2期	丹麦	Action Pharma A/S	2010-10-01
心脏瓣膜疾病	临床2期	丹麦	Action Pharma A/S	2010-10-01
肾脏疾病	临床2期	丹麦	Action Pharma A/S	2010-10-01
急性肾损伤	临床2期	美国	Action Pharma A/S	2008-03-01
多器官功能衰竭	临床2期	欧洲	Action Pharma A/S	-
心肌梗塞	临床2期	欧洲	Action Pharma A/S	-
再灌注损伤	临床2期	欧洲	Action Pharma A/S	-